EP Patent

EP1450799B9 — Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers

Assigned to Bayer Healthcare LLC · Expires 2007-05-09 · 19y expired

What this patent protects

This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer.

USPTO Abstract

This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP1450799B9
Jurisdiction
EP
Classification
—
Expires
2007-05-09
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Healthcare LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.